SOHM, Inc. (SHMN)
OTCMKTS · Delayed Price · Currency is USD
0.0018
+0.0001 (2.86%)
Jul 16, 2025, 2:26 PM EDT
SOHM, Inc. Revenue
In the year 2012, SOHM, Inc. had annual revenue of $1.30M, down -3.27%. SOHM, Inc. had revenue of $291.24K in the quarter ending December 31, 2012, with 35.18% growth.
Revenue
1.30M
Revenue Growth
+115.16%
P/S Ratio
3.38
Revenue / Employee
8.94K
Employees
145
Market Cap
4.38M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
SOHM, Inc. News
- 16 days ago - SOHM, Inc. Appoints Ravi Kapoor as an Independent Director - Accesswire
- 22 days ago - SOHM, Inc. Sets Strategic Goals to Enter Biotechnology-Driven Cosmeceuticals Market - Accesswire
- 5 weeks ago - SOHM Inc. Welcomes Dr. Larissa Karnaoukhova as New Vice President of Operations - Accesswire
- 6 weeks ago - SOHM Inc. Welcomes Dr. Lucia Piccotti to Offer Expert Guidance on Cosmeceutical and Personal Health Product Research and Development - Accesswire
- 2 months ago - SOHM, Inc., Unveils Genetically Engineered Ovarian Cancer Cell Line Using ABBIE(TM) Platform to Accelerate GYS1 Drug Discovery - Accesswire
- 2 months ago - Dr. Leonardo Mirandola Joins SOHM, Inc. as an Advisory Board to Advance CAR-T Cell Projects Toward Clinical Trials and Commercialization - Accesswire
- 2 months ago - SOHM Inc. Awarded European Patent for Innovative ABBIE Genome Editing Technology - Accesswire
- 2 months ago - SOHM, Inc. Agrees to Licensing for Investigational and Pre-Clinical Studies for Groundbreaking ABBIE Genome Editing Technology for CAR-T Cell Cancer Therapies - Accesswire